ANEBULO PHARMACEUTICALS, INC. Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price
ANEBULO PHARMACEUTICALS, INC. (ANEB) reported Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price of $1.17 per share for the 12-month period ending 2025-06-30, per its 10-K filed 2025-09-29.
Financial Statements › Notes › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice · last filed 2025-09-29
- ANEBULO PHARMACEUTICALS, INC. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for the quarter ending 2023-09-30 was $3.27, a 40.44% decline year-over-year.
- ANEBULO PHARMACEUTICALS, INC. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for the quarter ending 2022-09-30 was $5.49.
- ANEBULO PHARMACEUTICALS, INC. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for fiscal 2025 was $1.17, a 57.61% decline from fiscal 2024.
- ANEBULO PHARMACEUTICALS, INC. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for fiscal 2024 was $2.76, a 16.62% decline from fiscal 2023.
- ANEBULO PHARMACEUTICALS, INC. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for fiscal 2023 was $3.31, a 42.53% decline from fiscal 2022.
- ANEBULO PHARMACEUTICALS, INC. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for fiscal 2022 was $5.76, a 164.22% increase from fiscal 2021.
| Period end | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 3 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 6 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 9 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 12 month |
|---|---|---|---|---|
| 2025-06-30 | $1.17 10-K · filed 2025-09-29 | |||
| 2025-03-31 | $1.56 10-Q · filed 2025-05-13 | |||
| 2024-12-31 | $1.56 10-Q · filed 2025-02-14 | |||
| 2024-06-30 | $2.76 10-K · filed 2024-09-25 | |||
| 2024-03-31 | $3.00 10-Q · filed 2024-05-15 | |||
| 2023-12-31 | $3.03 10-Q · filed 2024-02-13 | |||
| 2023-09-30 | $3.27 10-Q · filed 2023-11-14 | |||
| 2023-06-30 | $3.31 10-K · filed 2023-09-22 | |||
| 2023-03-31 | $3.31 10-Q · filed 2023-05-11 | |||
| 2022-12-31 | $3.31 10-Q · filed 2023-02-10 | |||
| 2022-09-30 | $5.49 10-Q · filed 2022-11-10 | |||
| 2022-06-30 | $5.76 10-K · filed 2022-09-09 | |||
| 2022-03-31 | $6.16 10-Q · filed 2022-05-11 | |||
| 2021-12-31 | $6.90 10-Q · filed 2022-02-11 | |||
| 2021-06-30 | $2.18 10-K · filed 2021-09-22 | |||
| 2021-03-31 | $2.18 10-Q · filed 2021-06-21 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ACTUATE THERAPEUTICS, INC. (ACTU) | United States | $0.015B | |
| Lantern Pharma Inc. (LTRN) | United States | $0.015B | -2.87 |
| Citius Pharmaceuticals, Inc. (CTXR) | United States | $0.016B | -133.06 |
| Tvardi Therapeutics, Inc. (TVRD) | United States | $0.014B | |
| Vyome Holdings, Inc (HIND) | United States | $0.014B | -1.38 |
| Korsana Biosciences, Inc. (CYCN) | United States | $0.016B | |
| BullFrog AI Holdings, Inc. (BFRG) | United States | $0.014B | |
| LISATA THERAPEUTICS, INC. (LSTA) | United States | $0.014B | -2.13 |
| Pasithea Therapeutics Corp. (KTTA) | United States | $0.017B | -0.81 |
| Vistagen Therapeutics, Inc. (VTGN) | United States | $0.013B | -0.14 |